At a glance
- Originator Abbott Laboratories
- Class Antineoplastics; Benzoxazines
- Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Jan 2013 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 08 Feb 2001 Preclinical development for Cancer in USA (unspecified route)
- 21 Sep 1998 No development reported - Preclinical for Cancer in USA (unspecified route)